Elucidation of the role of the EPO-FGF23 signaling pathway in hereditary anemia and chronic hemolytic diseases will add to the understanding of the pathophysiology of the diseases, of bone mineralization disorders complicating chronic hemolytic diseases, and might provide new targets for treatment downstream of EPO. Here, EPO is linked to hereditary anemia.